Thyroid Mutations and Implications for Clinical Treatment by Emily S. Zhang, Joseph Scharpf

“…DTCs can have BRAF-like or RAS-like pathways of driver mutations with strong genotype–phenotype correlations, which are targetable through multikinase and tyrosine kinase inhibitors. Case studies illustrate how molecular profiling can guide clinical decisions and enhance treatment outcomes. …”
Get full text

Chronic Eosinophilic Leukemia Presenting as Cardiac Failure by Nii Boi-Doku Pepra-Ameyaw, William Kwasi Ghunney, Eugene Baafi Ampofo, Edeghonghon Olayemi

“…Good symptomatic control was achieved using hydroxyurea after which haematologic and cytogenetic remission was achieved after 12 weeks on a tyrosine kinase inhibitor. Physicians working in low resource environments should exclude clonality in patients presenting with eosinophilia and end-organ damage.…”
Get full text

Management of chimeric antigen receptor T-cell-related toxicity of a patient affected by cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, follo... by G. Menardi, A. Castellino, C. Castellino, M. E. Bersia, E. Grande, G. Fraternali, M. Massaia, C. Fruttero

“…Post-Bruton’s tyrosine kinase inhibitor failure, the prognosis remains unfavorable. …”
Get full text

“Subtype-precise” therapy leads diagnostic and therapeutic innovations: a new pattern for precision treatment of breast cancer by ZHANG Siwei, MA Ding, JIANG Yizhou, SHAO Zhimin

“…They divided it into four molecular subtypes and proposing corresponding precision treatment strategies: canonical luminal subtype (SNF1), sensitive to endocrine therapy; immunogenic subtype (SNF2), amenable to immunotherapy; proliferative subtype (SNF3), treatable by CDK4/6 inhibitors; and receptor tyrosine kinase-driven subtype (SNF4), targetable with tyrosine kinase inhibitors. …”
Get full text

The Expression and Action of Decay-Accelerating Factor (CD55) in Human Malignancies and Cancer Therapy by Jan-Henrik Mikesch, Kathrin Schier, Antje Roetger, Ronald Simon, Horst Buerger, Burkhard Brandt

“…Here DAF seems to exert different functions beyond its immunological role such as e.g. promotion of tumorigenesis, decrease of complement mediated tumor cell lysis, autocrine loops for cell rescue and evasion of apoptosis, neoangiogenesis, invasiveness, cell motility, and metastasis via oncogenic tyrosine kinase pathways and specific seven-span transmembrane receptors (CD97) binding. …”
Get full text

Brigatinib treatment in a patient with advanced NSCLC with XPO1-ALK fusion: a case report by Yang Zhang, Ke-jie Li, Can Wang, Chang-lin Zou, Meng Su

“…Patients with ALK-rearranged non-small cell lung cancer (NSCLC) who are treated with ALK tyrosine kinase inhibitors (ALK TKIs) have better prognoses. …”
Get full text

Regulation of Endothelial Adherens Junctions by Tyrosine Phosphorylation by Alejandro Pablo Adam

“…Inflammatory conditions promote the disassembly of the adherens junction and a loss of intercellular adhesion, creating openings or gaps in the endothelium through which small molecules diffuse and leukocytes transmigrate. Tyrosine kinase signaling has emerged as a central regulator of the inflammatory response, partly through direct phosphorylation and dephosphorylation of the adherens junction components. …”
Get full text

BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA by Ugo Testa, Elvira Pelosi, Germana Castelli, Patrizia Chiusolo

“…Furthermore, recent studies in newly diagnosed B-ALL patients have led in Philadelphia chromosome-positive patients to the development of chemotherapy-free regimens based on tyrosine kinase inhibitors plus Blinatumomab and in Philadelphia chromosome-negative patients to improvement in outcomes using chemotherapy regimens that have incorporated Blinatumomab in the consolidation phase of treatment. …”
Get full text

Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia by Justine Chan, Paarth Shah, Guillermo Moguel-Cobos

“…Nilotinib is a tyrosine kinase inhibitor used to treat patients with chronic myeloid leukemia (CML). …”
Get full text

Experimental and Density Functional Theory Characteristics of Ibrutinib, a Bruton’s Kinase Inhibitor Approved for Leukemia Treatment by Ali I. Ismail

“…Ibrutinib, a Bruton’s tyrosine kinase that plays an essential role in the B-cell development and cancer cells, has been recently approved to treat chronic, lymphocytic, and other types of leukemia. …”
Get full text

Current developments in personalized treatment strategies for elderly acute myelogenous leukemia patients by Xueting Hou, Jizhang Bao

“…Acute myelogenous leukemia(AML) is a life-threatening hematologic malignancy that predominantly affects the elderly.Currently, chemotherapy and hematopoietic stem cell transplantation are the primary treatment modalities for AML, though their clinical application is limited in older patients.Recent years have seen the development of novel molecular targeted therapies, such as isocitrate dehydrogenase 1/2 (IDH1/2) and Feline macrophage stimulator-like tyrosine kinase 3 (FLT3) inhibitors, as well as individualized approaches like chimeric antigen receptor T-cell (CAR-T) therapy.However, due to patient heterogeneity and drug resistance, treatment outcomes for elderly AML remain unsatisfactory, underscoring the need for more precise and safer individualized treatment strategies.The combination of chemotherapy with novel targeted or immunotherapies shows promise as a future treatment direction.This research reviews the latest advances in the treatment of elderly AML, with a focus on achieving more individualized and safer therapeutic approaches.…”
Get full text

Recurrent Gastrointestinal Hemorrhage in Children with Philadelphia-Positive B-Cell Acute Lymphoblastic Leukemia Treated with Dasatinib: Case Reports by Xin Liao, Yuxia Guo, Yali Shen, Jianwen Xiao

“…Dasatinib, a second-line tyrosine kinase inhibitor (TKI), has been widely used in chronic myeloid leukemia (CML) and Philadelphia-positive B-cell acute lymphoblastic leukemia (Ph + B-ALL). …”
Get full text

Recurrence of Chronic Myeloid Leukemia during Pregnancy Subsequently Achieving Complete Medical Remission by Sasha Mikhael, Ashlee Pascoe, Joseph Prezzato

“…The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) in reproductive-aged women poses major dilemmas concerning its associated teratogenicity as observed in many animal studies. …”
Get full text

Successful Treatment of Crizotinib-Induced Fulminant Liver Failure: A Case Report and Review of Literature by Kyle Kreitman, Satheesh P. Nair, Jiten P. Kothadia

“…Crizotinib is a first-line tyrosine kinase inhibitor used for the treatment of metastatic lung cancer. …”
Get full text

Challenges in the Diagnosis and Management of Patients with Fibrosing Interstitial Lung Disease by Leslie B. Tolle

“…Patients with some fibrosing ILDs may respond well to immunosuppressants, but even patients who respond well to immunosuppressants initially may later show deterioration despite appropriate management. The tyrosine kinase inhibitor nintedanib has been approved for the treatment of idiopathic pulmonary fibrosis, other chronic fibrosing ILDs with a progressive phenotype, and systemic sclerosis-associated ILD. …”
Get full text

Belzutifan for the treatment of renal cell carcinoma by Xiancheng Wu, David Lazris, Risa Wong, Scott S. Tykodi

“…Belzutifan has demonstrated activity in clinical trials as a front- and later-line therapy, and in combination with tyrosine kinase inhibitors. It has been largely well tolerated, although anemia represents a common on-target side effect and, along with hypoxia, requires monitoring during treatment. …”
Get full text

Transient Complete Recovery of Chronic Refractory Idiopathic Thrombocytopenic Purpura after Treatment with Monoclonal Antibody Targeting SARS-CoV-2 Spike Protein by Pooja Gogia, Yiqing Xu

“…Therapy for ITP relies on competing and inhibiting the autoantibody binding and destruction (intravenous immunoglobulin and anti-D immunoglobulin and spleen tyrosine kinase (Syk) inhibitor fostamatinib), augmenting platelet production (thrombopoietin receptor agonists), immunosuppression to reduce the autoantibody production, as well as splenectomy. …”
Get full text

A rare vascular manifestation in chronic myeloid leukemia: a case report and literature review of Bier's spot development during nilotinib treatment by Ahmed Alsaati, Turki Hakami, Sultan Bajawi, Gamil Mohammed, Nouf Bajawi, Nadya Al-Faraidy

“…This case emphasizes the need to recognize potential vascular side effects of tyrosine kinase inhibitors and highlights Bier's spots as a benign but remarkable manifestation in patients undergoing nilotinib therapy. …”
Get full text

The Discovery of Novel Experimental Therapies for Inflammatory Arthritis by Charles J. Malemud

“…Over the past few years, sphingosine-1-phosphate, interleukin-7 receptor, spleen tyrosine kinase, extracellular signal-regulated kinase, mitogen-activated protein kinase 5/p38 kinase regulated/activated protein kinase, micro-RNAs, tumor necrosis factor-related apoptosis inducing ligand and the polyubiquitin-proteasome pathway were identified as promising novel targets for potential antiarthritis drug development. …”
Get full text

A Case Report with Severe Thrombocytopenia Induced by Axitinib by Ulkuhan I. Koksal, Janeiro Valle Goffin, Brian Lewis, Oliver A. Sartor, Elizaveta Belyaeva, Francisco Socola, Pedro C. Barata

“…Axitinib is an oral, second-generation tyrosine kinase inhibitor that is selective for vascular endothelial growth factor receptors (VEGFR). …”
Get full text